Plan to attend the following Supported Symposia and Product Theaters:
See the full Congress online program here.
Saturday, July 6, 11:30-12:45
**Lunch will be served as part of all Supported Symposia held on Saturday
|
Transforming Research Into Clinical Reality: Takeda’s Gene Therapy Program in Hemophilia
Meeting Room 203/204 Supported by Takeda |
|
|
The Role of the Protein C System in a Rare Disorder and its Impact in Critical Care
Meeting Room 210/211 Supported by Takeda |
|
|
The Evolution of Turning Genes Into Medicine: Leveraging Innovation To Create a Path Forward
Meeting Room 212/213 Supported by Spark Therapeutics, Inc. |
|
|
Understanding the Outcomes of Anticoagulation: Insights From the GARFIELD Registries
Meeting room 219/220 Supported by TRI |
|
|
Defining a New Paradigm for the Management of Acquired Thrombotic Thrombocytopenic Purpura
Meeting Room 106 Supported by Sanofi Genzyme |
|
|
Inhibitors: Prevention and Evolving Treatment Paradigms
Meeting Room 109 Supported by GRIFOLS |
|
|
A Decade of Innovation: from DOACs to Reversal Agents
Meeting Room 110 Supported by Boehringer Ingelheim |
|
Sunday, July 7, 07:00-07:45
|
aTypical HUS: Finding a Needle in a Haystack
Meeting Room 219/220 Supported by Alexion Pharmaceuticals, Inc. |
|
Sunday, July 7, 12:15-13:00
|
|
Prophylaxis in Hemophilia A at Modest Doses Impacts the Clinical Outcomes
Product Theater B Supported by GRIFOLS |
|
|
Update on HIT – from Pathophysiology to Treatment
Product Theater C Supported by Aspen Pharma |
|
|
Sunday, July 7, 13:15-14:30
|
Anticoagulation for the Management of VTE in the NOAC era
Melbourne Room 1 Supported by Bristol-Myers Squibb/Pfizer |
|
|
Introducing Esperoct®* (turoctocog alfa pegol), a New Extended Half-Life rFVIII — a Continuing Commitment to Patients with Haemophilia A
Melbourne Room 2 Sponsored by Novo Nordisk *This product is not approved in Australia |
|
|
The Future of Haemophilia A: Discussing SubQ-8, a New Subcutaneous FVIII Development Based on Simoctocog Alfa
Meeting Room 203/204 Supported by Octapharma |
|
|
Taking Action in Hemophilia A: Transforming Patient Outcomes Through Innovation
Meeting Room 210/211 Supported by Takeda |
|
|
|
Supporting Clinical Decision Making in Hemostasis by Innovative Diagnostic Solutions
Meeting Room 219/220 Supported by Roche |
|
Monday, July 08, 07:00-07:45
|
VTE Prophylaxis and Improved Patient Outcomes in Orthopedic Surgery: How to Engage the Surgeon
Meeting Room 219/220 Supported by Cardinal Health |
|
Monday, July 08, 12:15-13:15
|
Quantra, a Novel Viscoelastic Device for the Management of Acute Bleeding
Product Theater A Supported by Stago |
|
|
|
The Chronic Risk of Arterial and Venous Thrombosis: Managing Prevention with NOACs
Product Theater C Supported by Bayer AG |
|
|
Think Again About vWD: Deliver Control To The Patient
Product Theater D Supported by CSL Behring |
|
Monday, July 08, 13:15-14:30
|
Gene Transfer Gene Therapy: From Bench to Bedside
Melbourne Room 1 Supported by BioMarin Pharmaceutical Inc. |
|
|
Conveniently Protecting What Matters: Nuwiq® (Simoctocog Alfa) in PUPs and Personalised Prophylaxis
Melbourne Room 2 Supported by Octapharma |
|
|
What Everyone Should Know About Elevating Standards of Care in Haemophilia
Meeting Room 203/204 Supported by Sanofi Genzyme and Sobi |
|
|
Reversal of Specific Direct Novel Oral Anticoagulants in Patients Experiencing Life-Threatening Bleeds
Meeting Room 210/211 Portola Pharmaceuticals |
|
|
Transformative Science in an Era of Comprehensive Care: From Lab to Life
Meeting Room 212/213 Supported by Pfizer |
|
|
Tuesday, July 9, 12:15-13:00
|
|
|
Tuesday, July 9, 13:15-14:30
|
Considering Emergent Approaches to Overcome Challenges for People With Haemophilia A Without FVIII Inhibitors
Melbourne Room 2 Suported by Roche |
|
|
Managing Thrombotic Risk with Microvesicles: Ready for the Clinics?
Meeting Room 203/204 Supported by Stago |
|
|
Harnessing Innovation to Transform Standards of Care in VWD and cTTP
Meeting Room 210/211 Supported by Takeda |
|
|
|
Anticoagulation in Active Cancer Patients: How NOACs Changed Clinical Practice
Meeting Room 219/220 Supported by Bayer AG |
|
|
New Light Shed on VTE Prophylaxis in Medical Patients: The Current State of the art
Meeting Room 109/110 Suuprted by Sanofi |
|